Harmony Biosciences Holdings, Inc. (HRMY): Cost of Revenue
$198.34M
Year ended 2025-12-31
$235.91M
Trailing 12 months to 2026-06-30
+33.4%
3-year compound annual growth
+48.2%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $198.34M | +26.5% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $156.81M | +29.3% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $121.24M | +45.2% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $83.48M | +50.4% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $55.52M | +100.2% | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $27.74M | n/m | 2023-02-21, From 2020-01-01 |
| 2019-12-31 | $1.58M | n/a | 2022-02-28, From 2019-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $198.34M | +26.5% |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $15.91M | +41.9% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2024-12-31 | $6.23M | n/a |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $317.31M | +24.9% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $12.98M | +19.3% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $326.20M | -52.1% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $149.75M | -12.1% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $363.83M | +1.6% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $74.56M | -4.3% |
Compare HRMY, IONS, MDGL, COLL side by side · Screen every company in Pharmaceutical Preparations ↗